J.P. Morgan Sees Genmab Outlook Brightening After Drug Trial Data
J.P. Morgan analysts say Genmab’s revenue growth outlook over the next decade looks more certain after strong results in late-stage trials of Rina-S and Epkinly.
J.P. Morgan analysts say Genmab’s revenue growth outlook over the next decade looks more certain after strong results in late-stage trials of Rina-S and Epkinly.